Full text is available at the source.
Abstract
This nonrandomized clinical trial assesses associations between psilocybin therapy and changes in systemic markers of inflammation in people with Parkinson disease.
- Psilocybin therapy may be linked to alterations in markers related to inflammation.
- Changes in mitochondrial stress could also be associated with psilocybin therapy.
- The study focuses on individuals with Parkinson disease and mood dysfunction.
Simplified